PDCD1 and familial pancreatic carcinoma: In addition, programmed death‐ligand 1 (PD‐L1)‐positive responses in more than half of the cancer cells within tumors indicated good response to PD‐1 inhibitor therapy in patients with non‐small cell lung cancer.86 PD‐L1 overexpression in pancreatic cancer cells is thus possibly predictive of the response to anti‐PD‐1 therapy.